The NLRP3 inflammasome is activated by structurally unrelated danger signals, and how this promiscuous sensor is activated remains a central open question in innate immunity. A 2013 study (Iyer et al., Immunity) proposed that cardiolipin, a mitochondria-specific phospholipid externalized to the outer mitochondrial membrane during dysfunction, binds the leucine-rich repeat (LRR) region of NLRP3 and both docks and activates the inflammasome, leaving open three linked questions: the biochemical mechanism by which cardiolipin binding triggers NLRP3 activation, how cardiolipin cooperates with mitochondrial DNA and other mitochondrial danger signals to determine whether mitochondrial dysfunction yields inflammasome activation, apoptosis, or necrosis, and whether NLRP3-mediated inflammation accounts for human linezolid-associated myelosuppression. Thirteen years of follow-up work has built detailed structural and cell-biological models of NLRP3 activation (NEK7 licensing, inactive cage to active disc transition, phosphatidylinositol-4-phosphate-dependent recruitment to the dispersed trans-Golgi network, signal-induced phase separation), but the cardiolipin-NLRP3 interaction itself has never been structurally defined or cleanly genetically validated, and reviews through 2026 still treat cardiolipin as one of several unconfirmed candidate lipid ligands. The problem remains open.

Background

Innate immune cells assemble inflammasomes — multi-protein complexes that activate the cysteine protease caspase-1 — in response to intracellular danger. The best-studied sensor, NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3), drives caspase-1-dependent maturation of the pro-inflammatory cytokines IL-1β and IL-18 and gasdermin D-mediated pyroptotic cell death. NLRP3 consists of an N-terminal pyrin domain (PYD) that nucleates the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD), a central NACHT nucleotide-binding/oligomerization domain, and a C-terminal leucine-rich repeat (LRR) region. Unlike other inflammasome sensors, which detect defined ligands, NLRP3 is activated by chemically unrelated stimuli — extracellular ATP, pore-forming toxins, uric acid and cholesterol crystals, silica, amyloid aggregates — leading to the long-standing proposal that these converge on a common endogenous ligand or cellular perturbation. Inflammasome activation additionally requires a preceding priming step (e.g. Toll-like receptor signaling), which induces NLRP3 and pro-IL-1β expression and post-translational changes.

Mitochondria were proposed as this convergence point. Mitochondrial dysfunction, mitochondrial reactive oxygen species (ROS), and the release of mitochondrial DNA (mtDNA) — particularly oxidized mtDNA, which can bind NLRP3 during apoptosis — have all been implicated. Iyer et al. (Immunity 2013) added a lipid candidate: cardiolipin, a four-acyl-chain anionic phospholipid normally confined to the inner mitochondrial membrane (and bacterial membranes), which translocates to the outer mitochondrial membrane when mitochondria are damaged. Using the oxazolidinone antibiotic linezolid as a ROS-independent NLRP3 agonist, they showed that (i) both ROS-dependent and ROS-independent NLRP3 activation converge on mitochondrial dysfunction and are blocked by the mitochondrial stabilizer cyclosporine A; (ii) cardiolipin binds NLRP3 directly, mapped by protein-lipid overlay and cardiolipin-bead assays with tagged fragments to the LRR region (constructs containing aa 535-719 bound; isolated PYD and NACHT domains did not); (iii) interfering with cardiolipin synthesis (palmitate treatment, siRNA to cardiolipin synthase) selectively impaired NLRP3 — but not NLRC4 or AIM2 — inflammasome activation and the stimulus-dependent association of NLRP3 with mitochondria; and (iv) in mice, linezolid-induced suppression of bone marrow erythroid precursors was Nlrp3-dependent. Cardiolipin is also a known platform for apoptotic pathways (cytochrome c release and apoptosome formation; caspase-8 activation), which motivated the authors' explicitly unresolved question of what permits cardiolipin-dependent NLRP3 activation without triggering full apoptosis. Subsequent work established that the LRR region is also the binding site for NEK7, an essential protein cofactor for NLRP3 activation, and structural studies defined inactive autoinhibited NLRP3 oligomers (cage/decamer) and an active NLRP3-NEK7-ASC disc — none of which involves cardiolipin — while other studies placed NLRP3 recruitment on dispersed trans-Golgi network membranes through binding of phosphatidylinositol-4-phosphate (PI4P).

Problem Statement

The problem, as posed by the source work and left unresolved by the subsequent literature, is to establish the molecular mechanism by which externalized mitochondrial cardiolipin activates the NLRP3 inflammasome, and how this lipid signal cooperates with other mitochondrial danger signals to determine cell fate. Specifically: (1) Determine whether cardiolipin directly binds NLRP3 in cells, identify the cardiolipin-interaction determinants on the NLRP3 LRR region (residues and binding mode), and establish the mechanism by which this binding promotes NLRP3 activation — including whether and how it shifts the conformational/oligomeric equilibrium of NLRP3 (autoinhibited cage/decamer toward the active disc capable of ASC recruitment and caspase-1 activation) — or alternatively demonstrate that cardiolipin is not required for NLRP3 activation. (2) Determine the relative contributions and required combinations of cardiolipin, oxidized mitochondrial DNA, and other mitochondrial danger-associated molecular patterns to NLRP3 activation — in particular whether the source's proposal that mitochondrial DNA in concert with cardiolipin regulates the response to mitochondrial dysfunction is correct. (3) Identify the molecular determinants and sequence of events that decide whether mitochondrial dysfunction with cardiolipin externalization leads to NLRP3 inflammasome activation rather than, or concurrently with, apoptotic caspase cascades that also converge on cardiolipin (cytochrome c/apoptosome, caspase-8) or necrosis. (4) As a translational endpoint of the same mechanism, establish whether NLRP3-mediated inflammation accounts for human linezolid-associated myelosuppression, beyond the Nlrp3-dependent bone-marrow effects demonstrated in mice. Resolving the question requires (1)–(3); the two branches of (1) are mutually exclusive alternatives — a solution either establishes how cardiolipin promotes NLRP3 activation or demonstrates that cardiolipin is not required — while (4) is a translational corollary of the same mechanism and is not required to resolve the molecular question. Answers that re-describe adjacent activation mechanisms (NEK7 licensing, PI4P-dependent trans-Golgi recruitment, phase separation) without resolving cardiolipin's specific role do not answer this question.

References

  1. Iyer SS, He Q, Janczy JR, et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity (2013). DOI: 10.1016/j.immuni.2013.08.001. https://doi.org/10.1016/j.immuni.2013.08.001 (source paper; full text at PMC3779285)
  2. Shimada K, Crother TR, Karlin J, et al. Oxidized Mitochondrial DNA Activates the NLRP3 Inflammasome during Apoptosis. Immunity (2012). DOI: 10.1016/j.immuni.2012.01.009. https://doi.org/10.1016/j.immuni.2012.01.009
  3. Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nature Immunology (2011). DOI: 10.1038/ni.1980. https://doi.org/10.1038/ni.1980
  4. Muñoz-Planillo R, Kuffa P, Martínez-Colón GJ, Smith BL, Rajendiran TM, Núñez G. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity (2013). DOI: 10.1016/j.immuni.2013.05.016. https://doi.org/10.1016/j.immuni.2013.05.016
  5. Allam R, Lawlor KE, Yu EC, et al. Mitochondrial apoptosis is dispensable for NLRP3 inflammasome activation but non-apoptotic caspase-8 is required for inflammasome priming. EMBO Reports (2014). DOI: 10.15252/embr.201438463. https://doi.org/10.15252/embr.201438463
  6. He Y, Zeng M, Yang D, Motro B, Núñez G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature (2016). DOI: 10.1038/nature16959. https://doi.org/10.1038/nature16959
  7. Shi H, Wang Y, Li X, et al. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nature Immunology (2016). DOI: 10.1038/ni.3333. https://doi.org/10.1038/ni.3333
  8. Zhong Z, Liang S, Sanchez-Lopez E, et al. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature (2018). DOI: 10.1038/s41586-018-0372-z. https://doi.org/10.1038/s41586-018-0372-z
  9. Chen J, Chen ZJ. PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation. Nature (2018). DOI: 10.1038/s41586-018-0761-3. https://doi.org/10.1038/s41586-018-0761-3
  10. Elliott EI, Miller AN, Banoth B, et al. Cutting Edge: Mitochondrial Assembly of the NLRP3 Inflammasome Complex Is Initiated at Priming. Journal of Immunology (2018). DOI: 10.4049/jimmunol.1701723. https://doi.org/10.4049/jimmunol.1701723
  11. Vince JE, De Nardo D, Gao W, et al. The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and -7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1β Activation. Cell Reports (2018). DOI: 10.1016/j.celrep.2018.10.103. https://doi.org/10.1016/j.celrep.2018.10.103
  12. Sharif H, Wang L, Wang WL, et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome. Nature (2019). DOI: 10.1038/s41586-019-1295-z. https://doi.org/10.1038/s41586-019-1295-z
  13. Swanson KV, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nature Reviews Immunology (2019). DOI: 10.1038/s41577-019-0165-0. https://doi.org/10.1038/s41577-019-0165-0
  14. Andreeva L, David L, Rawson S, et al. NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation. Cell (2021). DOI: 10.1016/j.cell.2021.11.011. https://doi.org/10.1016/j.cell.2021.11.011
  15. Hochheiser IV, Pilsl M, Hagelueken G, et al. Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3. Nature (2022). DOI: 10.1038/s41586-022-04467-w. https://doi.org/10.1038/s41586-022-04467-w
  16. Pizzuto M, Pelegrin P, Ruysschaert J-M. Lipid-protein interactions regulating the canonical and the non-canonical NLRP3 inflammasome. Progress in Lipid Research (2022). DOI: 10.1016/j.plipres.2022.101182. https://doi.org/10.1016/j.plipres.2022.101182 (full text at PMC7613582)
  17. Xiao L, Magupalli VG, Wu H. Cryo-EM structures of the active NLRP3 inflammasome disc. Nature (2023). DOI: 10.1038/s41586-022-05570-8. https://doi.org/10.1038/s41586-022-05570-8
  18. Zou G, Tang Y, Yang J, et al. Signal-induced NLRP3 phase separation initiates inflammasome activation. Cell Research (2025). DOI: 10.1038/s41422-025-01096-6. https://doi.org/10.1038/s41422-025-01096-6 (full text at PMC12134225)
  19. Pizzuto M, Monteleone M, Burgener SS, et al. Cardiolipin inhibits the non-canonical inflammasome by preventing LPS binding to caspase-4/11. EMBO Journal (2025). DOI: 10.1038/s44318-025-00507-z. https://doi.org/10.1038/s44318-025-00507-z
  20. Chai Z, Zhou Y, Hossain S, et al. Cardiolipin's multifaceted role in immune response: a focus on interacting proteins. Frontiers in Immunology (2025). DOI: 10.3389/fimmu.2025.1680326. https://doi.org/10.3389/fimmu.2025.1680326 (full text at PMC12719303)
  21. Anand PK, Aljadeed NM. Spatial control of NLRP3 inflammasome assembly by membrane lipid composition. Communications Biology (2026). DOI: 10.1038/s42003-026-10541-0. https://doi.org/10.1038/s42003-026-10541-0 (full text at PMC13291237)
  22. Boršić-Mlinarič E, Hafner-Bratkovič I. Diverse Scaffolds Facilitate NLRP3 Clustering and Inflammasome Formation in Response to Perturbations in Cell Homeostasis. BioEssays (2026). DOI: 10.1002/bies.70130. https://doi.org/10.1002/bies.70130
  23. De Matteis MA, Prodomo A, Sarno G. Lipid-NLRP3 interplay in inflammasome regulation. Advances in Biological Regulation (2026). DOI: 10.1016/j.jbior.2026.101161. https://doi.org/10.1016/j.jbior.2026.101161